1. トップページ
  2. 研究業績 > 主な国際学会発表

主な国際学会発表

2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 

2019

Akahane T Is non-alcoholic fatty liver disease a risk factor for chronic kidney disease? Akahane T, Namisaki T, Moriya K, Kawaratani H, Kaji K, Takaya H, Shimozato N, Sato S, Sawada Y, Nakanishi K, Furukawa M, Fujinaga Y, Tsuji Y, Yoshiji H EASL 2019 Austria 2019. 4.11

Yuki Tsuji Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein Tsuji Y, Kaji K, Saikawa S, Seki K, Sato S, Nakanishi K, Kawaratani H, Kitade M, Moriya K, Namisaki T, Yoshiji H EASL 2019 Austria 2019. 4.11

Sato S Efficacy of L-Carnitine on the ribavirin induced hemolytic anemia for patients with HCV infection Sato S, Moriya K, Namisaki T, Kaji K, Takaya H, Akahane T, Kawaratani H, Sawada Y, Fujinaga Y, Furukawa M, Yoshiji H EASL 2019 Austria 2019. 4.11

Fujinaga Y Identification of risk factors for histological progression with sequential liver biopsies in primary cholangitis patients Fujinaga Y, Namisaki T, Akahane T, Kaji K, Takaya H, Sato S, Moriya K, Kawaratani H, Sawada Y, Furukawa M, Tsuji Y, Yoshiji H EASL 2019 Austria 2019. 4.12

Sawada Y Combining probiotics and an angiotensin-2 type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Seki K, Takaya H, Okura Y, Kaji K, Shimozato N, Kitade M, Moriya K, Namisaki T, Akahane T, Yoshiji H EASL 2019 Austria 2019. 4.12

Namisaki T Effect of combined farnesoid X receptor agonist and angiotensin 2 receptor blocker on established liver fibrosis in rats Namisaki T, Kaji K, Nakanishi K, Tsuji Y, Sato S, Sawada S, Akahane T, Furukawa M, Fujinaga Y, Takaya H, Yoshiji H EASL 2019 Austria 2019. 4.12

Kaji K Rifaximin alleviates endotoxemia with improved intestinal hyperpermeability with partially modified fecal microbiota in cirrhotic patients Kaji K,Takaya H, Saikawa S, Sato S, Kawaratani H, Moriya K, Namisaki T, Akanahe T, Mitoro A, Yoshiji H EASL 2019 Austria 2019. 4.12

Fujinaga Y Identification of risk factors for histological progression with sequential liver biopsies in primary cholangitis patients Fujinaga Y, Namisaki T, Akahane T, Kaji K, Takaya H, Sato S, Moriya K, Kawaratani H, Sawada Y, Furukawa M, Tsuji Y, Yoshiji H APASL STC 2019 Tokyo 2019. 4.18

Sawada Y Combining probiotics and an angiotensin-2 type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Seki K, Takaya H, Okura Y, Kaji K, Shimozato N, Kitade M, Moriya K, Namisaki T, Akahane T, Yoshiji H APASL STC 2019 Tokyo 2019. 4.18

Kaji K Rifaximin alleviates endotoxemia with improved intestinal hyperpermeability with partially modified fecal microbiota in cirrhotic patients Kaji K,Takaya H, Saikawa S, Sato S, Kawaratani H, Moriya K, Namisaki T, Akanahe T, Mitoro A, Yoshiji H APASL STC 2019 Tokyo 2019. 4.18

2018

Kaji K Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting gut microbiota diversity Kaji K Internatioal Liver Symposium 2018 奈良 2018. 2.10

Tanaka A Are the Globe and UK-PBC scrore also effective for predicting risk in patients treated with bezafibrate in addition to ursodeoxycholic acid?:A validation study in Japan Tanaka A, Komori A, Abe M, Inao M, Namisaki T, Hashimoto N, Kawata K, Takahashi A, Ninomiya M, Honda A, Hong-Hon K, Arakawa M, Yamagiwa S, Joshita S, Sato K, Kaneko A, Kikuchi K, Itakura J, Nomura T, Kakisaka K, Yoshji H, and et al. EASL France 2018. 4.11

Shimozato N Effect of combined farnesoid X receptor agonist(INT747)and dipeptidyl peptidase-4 inhibitor(sitagliptin) on liver fibrosis Shimozato N, Namisaki T, Akahane T, Moriya K, Kitade M, Kawaratani H, Kaji K, Okura Y, Takaya H, Sawada Y, Nishimura N, Sato S, Saikawa S, Seki K, Furukawa M, Kubo T, Yoshjiji H EASL France 2018. 4.12

Takahashi A Health-Related quality of life in patients with autoimmune hepatitis Takahashi A, Moriya K, Ohira H, Arinaga-Hino T, Torimura T, Zeniya M, Abe M, Takaki A, Kng JH, Inui A, Fujisawa T, Yoshizawa K, Suzuki Y, Nakamoto N, Koike K, Yoshji H, and et al. EASL France 2018. 4.12

Yagi M Effect of nalfurafine hydrochloride for refractory pruritus in patients with primary biliary cholangitis: a multicenter, postmarketing single-arm, prospective study Yagi M, Tanaka A, Namisaki T, Abe M, Takahashi A, Honda A, Matsuzaki Y, Ohira H, Yoshiji H, Takikawa H EASL France 2018. 4.12

Namisaki T Biochemical response to ursodeoxycholic acid predicts histologic primary ciliary cholangitis progression Namisaki T, Fujinaga Y, Moriya K, Kitade M, Kaji K, Kawaratani H, Seki K, Takaya H, Sato S, Sawada Y, Akahane T, Yoshji H EASL France 2018. 4.12

Kitade M Possble liver regeneration and anti-fibrogenic effect of NOTCH1 selective inhibitor in the diseased liver model Kitade M, Kaji K, Yoshji H EASL France 2018. 4.13

Akahane T Moderate alcohol consumption protects against fatty liver in males Akahane T, Namisaki T, Kitade M, Kaji K, Takaya H, Shimozato N, Sato S, Yoshiji H EASL France 2018. 4.14

Takaya H Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity Takaya H, Kaji K, Saikawa S, Furukawa M, Sato S, Sawada Y, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H EASL France 2018. 4.14

Takaya H Ratio of Von Willebrand Factor to ADAMTS13 is a Novel Potential Biomarker for Early Diagnosis of HCC Takaya H, Namisaki T, Kitade M, Kaji K, Shimozato N, Akahane T, Moriya K, Kawaratani H, Sawada Y, Seki K, Sato S, Nakanishi K, Yoshiji H APASL 横浜 2018. 5.12

Sato S Pharmacological Activator of NRF2 Inhibits Hepatic Cancer Cell Growth with Attenuating Angiogenesis Sato S, Moriya K, Namisaki T, Kitade M, Kawaratani H, Takaya H, Kaji K, Okura Y, Shimozato N, Saikawa S, Yoshiji H APASL 横浜 2018. 5.12

Furukawa M The poor reactivity to ursodeoxycholic acid in patients with primary biliary cholangitis might affect the long-term prognosis through their gut dysbiosis. Furukawa M, Moriya K, Kaji K, Namisaki T, Seki K, Saikawa S, Sato S, Sawada Y, Takaya H, Okura Y, Shimozato N, Kawaratani H, Kitade M, Akahane T, Mitoro A, Yamao J, Yoshiji H AASLD サンフランシスコ 2018.11. 9

Sawada Y Combining probiotics and an angiotensin-Ⅱtype 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Seki K, Sato S, Takaya H, Okura Y, Kaji K, Shimozato N, Kitade M, Moriya K, Namisaki T, Akahane T, Yoshiji H AASLD サンフランシスコ 2018.11. 9

Kaji K Rifaximin alleviates endotoxemia with improvement of intestinal hyperpermeability and minor changes in fecal microbiota in cirrohotic patients with hepatic encephalopathy Kaji K, Saikawa S, Takaya H, Sato S, Kitade M, Moriya K, Namisaki T, Akahane T, Yoshiji H AASLD サンフランシスコ 2018.11. 9

Namisaki T Effect of combined farnesoid X receptor agonist and angiotensin Ⅱtype 1 receptor blocker on establishe liver fibrosis in rats.Namisaki T, Okura Y, Kaji K, Kitade M, Shimozato N, Moriya K, Sato S, Kawaratani H, Takaya H, Sawada Y, Seki K, Nakanishi K, Furukawa M, Tsuji Y, Fujinaga Y, Akahane T, Asada K, Yoshji H AASLD サンフランシスコ 2018.11.11

Takaya H Identification of von willebrand factor-to-ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma in patients with liver cirrhosis Takaya H, Namisaki T, Kaji K, Kitade M, Tsuji Y, Fujinaga Y, Furukawa M, Nakanishi K, Seki K, Sato S, Sawada Y, Saikawa S, Shimozato N, Kawaratani H, Asada K, Moriya K, Akahane T, Yoshiji H AASLD サンフランシスコ 2018.11.11

Akahane T Non-alcoholic fatty liver disease is not an independent risk factor for chronic kidney disease Akahane T, Namisaki T, Moriya K, Kawaratani H, Kaji K, Takaya H, Shimozato N, Sato S, Sawada Y, Seki K, Nakanishi K, Furukawa M, Fujinaga Y, Tsuji Y, Yoshiji H AASLD サンフランシスコ 2018.11.12

Tsuji Y Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of yes-associated protein Tsuji Y, Kaji K, Saikawa S, Kitade M, Moriya K, Namisaki T, Akahane T, Yoshiji H AASLD サンフランシスコ 2018.11.12

Fujinaga Y Possible risk factors for hstological progression with sequential liver biopsies in primary biliary cholangitis patients Fujinaga Y, Namisaki T, Moriya K, Kitade M, Kawaratani H, Kaji K, Seki K, Takaya H, Sawada Y, Akahane T, Sato S, Shimozato N, Saikawa S, Nakanishi K, Furukawa M, Tsuji Y, Asada K, Yoshiji H AASLD サンフランシスコ 2018.11.12

2017

Okamoto S Genetic Analysis in Japanese Kallmann Syndrome and Idiopathic Hypogonadotropic Hypogonadism Okamoto S, Ogata T, Yasuhara H, Okamoto A, Uejima M, Kurematsu Y, Mashitani T, Yoshiji H PITUITARY CONGRESS FLORIDA 15 2017. 3.30

Saikawa S Angiotensin ⅡReceptor Blocker Attenuates Human Cholangiocarcinoma through Inhibition of the Hippo-YAP Signaling Pathway Saikawa S, Kaji K, Nishimura N, Sato S, Yoshiji H APASL 長崎 2017. 4.10

Nishimura N Dual Therapy with Acyclic Retinoid and Angiotensin-ⅡReceptorⅠBlocker Ameliorates Chemically Induced Hepatocarcinogenesis in Diabetic OLETF Rats Nishimura N, Kitade M, Kaji K, Namisaki T, Moriya K, Takeda K, Kawaratani H, Sato S, Saikawa S, Yoshiji H APASL 長崎 2017. 4.10

Kaji K Antitumoral Effect of SGL T2 Inhibior against Human Liver Cancer Kaji K, Nishimura N, Sato S, Saikawa S, Yoshiji H APASL 長崎 2017. 4.10

Sato S Combination Treatment of DipeptidyⅠ Peptidase Ⅳ inhibitor(Sitagliptin) and Angiotnsin-ⅡTypeⅠReceptor Blocker(Losartan)Supresses Progression in a Nondiabetic Rat Model of Steatohepatitis Sato S, Namisaki T, Okura Y, Kaji K, Moriya K, Nishimura N, Saikawa S, Yoshiji H APASL 長崎 2017. 4.10

Yoshiji H Fibrosis and HCC in NASH Yoshiji H APASL 長崎 2017. 4.11

Noguchi R Novel oral plasminogen activator inhibitor-1 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rat NASH models. Noguchi R, Kaji K, Namisaki T, Moriya K, Kitade M, Nishimura N, Yoshji H AASLD ワシントン 2017.10.20

Takeda K Periostin cross-reacts with the renin-angiotensin system during liver fibrosis Takeda K, Noguchi R, Kitade M, Namisaki T, Moriya K, Okura Y, Kaji K, Nishimura N, Yoshiji H AASLD ワシントン 2017.10.20

Fujinaga Y Biochemical response to ursodeoxycholic acid predicts histologic primary biliary cholangitis progression Fujinaga Y, Namisaki T, Moriya K, Kitade M, Kawaratani H, Kaji K, Okura Y, Seki K, Takaya H, Sawada Y, Akahane T, Nishimura N, Sato S, Shimozato N, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Yoshiji H AASLD ワシントン 2017.10.20

Takaya H ADAMTS13 deficiency exacerbates acute liver failure with enhanced VWF accumulation and hepatic inflammation in mice. Takaya H, Kaji K, Kitade M, Seki K, Saikawa S, Nishimura N, Sato S, Sawada Y, Okura Y, Kawaratani H, Akahane T, Moriya K, Namisaki T, Mitoro A, Yoshiji H AASLD ワシントン 2017.10.22

Akahane T Light-to Moderate Alcohol Consumption Protects Against Fatty Liver and lmproves Insulin Resistance Akahane T, Fukui K, Yoshiji H AASLD ワシントン 2017.10.23

Shimozato N Beneficial effects of combined farnesoid X receptor agonist(INT747) and dipeptidyl peptidase-4 inhibitor(sitagliptin) on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis Shimozato N, Namisaki T, Moriya K, Kitade M, Takeda K, Kawaratani H, Kaji K, Okura Y, Takaya H, Sawada Y, Nishimura N, Sato S, Saikawa S, Seki K, Furukawa M, Nakanishi K, Kubo T, Yoshiji H AASLD ワシントン 2017.10.23

Sato S Pharmacological activator of NRF2, sulforaphane, inhibits hepatic cancer cell growth with attenuating angiogenesis. Sato S, Kaji K, Namisaki T, Moriya K, Kitade M, Kawaratani H, Takaya H, Okura Y, Shimozato N, Sawada Y, Saikawa S, Seki K, Yoshji H. AASLD ワシントン 2017.10.23

Yoshiji H New approaches to hepatic edema by tolvaptan in the elderly population of liver cirrhosis. Yoshiji H、Hiramine Y, Uojima H, Nakanishi H, Hiramatsu A, Iwamoto T, Kimura H, Kawaratani H, and et al. AASLD ワシントン 2017.10.23

2016

Namisaki T Liver fibrosis progression only predicts survival and ursodeoxycholic acid response in PBC patients AASL 東京 2016. 2.22

Noguchi R Serum ACE level as a new non-invasive fibrosis marker could be possible for HBV patients AASL 東京 2016. 2.22

Kawaratani H Predictive value of the efficacy of tolvaptan in patients with refractory ascites in liver cirrhosis AASL 東京 2016. 2.23

Kitade M Augmentation of hepatic progenitor cells-mediated liver regeneration by antifibrotic therapy AASL 東京 2016. 2.23

Nishimura N Ipragliflozin ameliorates liver fibrosis development in diabetic OLET rats AASL 東京 2016. 2.23

Okura Y, Namisaki T, Noguchi R, Takeda K, Moriya K, Kitade M, Nishimura N, Sato S, Sawada Y, Kawaratani H, Seki K, Kaji K, Yoshiji H Impact of the combination of dipeptidyl peptidase IV inhibitor and angiotensin-Ⅱtype 1 receptor blocker on hepatocarcinogenesis in a rat model of nonalcoholic steatohepatitis EASL Spain 2016. 4.15

Namisaki T, Okura Y, Sato S, Noguchi R, Moriya K, Kitade M, Takeda K, Nishimura N, Sawada Y, Seki K, Kawaratani H, Kaji K, Yoshiji H Antifirotic effects of combined treatment with farnesoid X receptor agonist and angiotensin-Ⅱtype1 receptor blocker on hepatic fibrogenesis in the rat model of nonalcoholic steatohepatitis EASL Spain 2016. 4.16

Yoshiji H Prevention for HCC from NASH/NAFLD JSH Single Topic Conference 金沢 2016. 9.22

Sato S Adaptation and limitation of RFA along the guideline of HCC treatment in the clinical practice JSH Single Topic Conference 金沢 2016. 9.22

Douhara A Tumor number is the most important factor to predict early recurrence post TACE in hepatocellular carcinoma JSH Single Topic Conference 金沢 2016. 9.22

Nishimura N Dual therapy with acyclic retinoid and angiotensin-Ⅱreceptor1 blocker attenuates chemically induced hepatocarcinogenesis in diabetic OLETF rats JSH Single Topic Conference 金沢 2016. 9.22

Douhara A Inside plastic stent is useful and safety for malignant biliary stenosis including Bismuth Ⅳ APDW 2016 神戸 2016.11.3

Sato S Sarcopenia impairs hepatic functional reserve of men with liver cirrhosis APDW 2016 神戸 2016.11.3

Nishimura N Sodium-glucose contransporter-2 inhibitor ameliorates liver fibrosis development Via improving insulin resistance in diabetic Otsuka Long-Evans Tokushima Fatty rats NAPDW 2016 神戸 2016.11.3

Kaji K DNMT1-deleted hepatocytes cause promoted replicative senescence and induce liver fibrosis development with global DNA hypomethylation AASLD Boston 2016.11.11

Nishimura N Dual therapy with acyclic retinoid and angiotensin-Ⅱreceptor1 blocker attenuates chemically induced hepatocarcinogenesis in diabetic OLETF rats AASLD Boston 2016.11.11

Sato S Combination treatment of dipeptidyl peptidase Ⅳ inhibitor and angiotensin-Ⅱtype 1 receptor blocker attenuates progression of nonalcoholic steatohepatitis in rats AASLD Boston 2016.11.13

Namisaki T Impact of the combination of Farnesoid Ⅹ receptor agonist and angiotensin-Ⅱtype1 receptor blocker on hepatic fibrogenesis in the rat model of nonalcoholic steatohepatitis AASLD Boston 2016.11.14

2015

Kitade M, Nishimura N, Yoshiji H Attenuation of liver fibrosis development by angiotensin 2-receptor blocker 1-treatment augments hepatocyte differentiation of hepatic progenitor cells AASLD SAN FRANCISCO 2015.11.14

Kaji K, Valentina M.Factor, Jesper B.Andersen, Marian E.Durkin, Jens U.Marquardt, Elizabeth A.Conner, Tanya Hoang, Yoshiji H, Snorri S.Thorgeirsson DNMT1 is essential for effective postnatal and regenerative growth of adult liver AASLD SAN FRANCISCO 2015.11.14

2014

Noguchi R, Yoshiji H, Namisaki T, Moriya K, Kitade M, Douhara A, Kawaratani H, Takeda K, Okura A, Nishimura N, Fukui H. Prevalance of hepatitis B reactivation in chemotherapy of solid tumors. JSH Single Topic Conference. 京都 2014.11.21

Namisaki T, Yoshiji H, Noguchi R, Moriya K, Kitade M, Aihara Y, Douhara A, Nishimura N, Takeda K, Kawaratani H, Fukui H Breast Cancer Resistance Protein(BCRP) Expression Predicts Outcome of Patients with Hepatocellular Carcinoma International Kyoto Liver Cancer Symposium:Emerging Strategies to HCC 京都 2014.6.7

Moriya K, Yoshiji H, Namisaki T, Noguchi R, Douhara A, Aihara Y, Kitade M, Kawaratani H, Nishimura N, Takeda K, Uejima M, Yoshida M, Mitoro A, Fukui H Does Inhibition of Renin Angiotensin System Affects Prognosis of Advanced Hepatocellular Carcinoma Receiving Sorafenib? International Kyoto Liver Cancer Symposium:Emerging Strategies to HCC 京都 2014.6.7

Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, Douhara A, Nishimura N, Takeda K, Kawaratani H, Fukui H Soluble VEGF Receptor-2 May Be a Predictive Marker of Suppressive Effective of BCAA on the Cumulative Recurrence of HCC International Kyoto Liver Cancer Symposium:Emerging Strategies to HCC 京都 2014.6.7

Aihara Y, Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Douhara A, Nishimura N, Takeda K, Kawaratani H, Fukui H Direct Renin Inhibitor Suppressed the Hepatocarcinogenesis Along with Anti-angiogenesis in Rats International Kyoto Liver Cancer Symposium:Emerging Strategies to HCC 京都 2014.6.7

Nishimura N, Kitade M, Yoshiji H, Noguchi R, Namisaki T, Moriya K, Takeda K, Aihara Y, Douhara A, Kawaratani H, Fukui H Acyclic Retinoid Augments Apoptosis of Hepatocellular Carcinoma Cells Under Insulin-Resistance Condition International Kyoto Liver Cancer Symposium:Emerging Strategies to HCC 京都 2014.6.7

Douhara A, Yoshiji H, Moriya K, Noguchi R, Namisaki T, Kitade M, Aihara Y, Nishimura N, Takeda K, Okura Y, Fukui H Tumor number is the most important factor for recurrence of hepatocellular carcinoma after tace as its initial treatment ILCA 京都 2014.9.5

Kitade M, Yoshiji H, Aihara Y, Noguchi R, Namisaki T, Douhara A, Nishimura N, Fukui H Direct renin inhibitor attenuates hepatocarcinogenesis via angiogenesis suppression in rats ILCA kyoto 2014.9.5

Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, Douhara A, Nishimura N, Takeda K, Okura Y, Fukui H Combined treatment of low dose sorafenib and clinically available safety agent; angiotensin-Ⅱreceptor blocker, significantly attenuated the hepatocarcinogenesis via angiogenesis suppression in the rat ILCA  京都 2014.9.5

2013

Fujimoto M, Uemura M, Takaya H, Matsuyama T, Morioka C, Ishikawa M, Kawaratani H, Isonishi A, Hayakawa M, 
Matsumoto M, Fujimura Y, Fukui H
Decreased ADAMT13 activity associated with endotoxemia may contribute to the development of patients with advanced liver cirrhosis
Jahrestagung der Gesellschaft fur Hamostase-und Thromboseforschung
ミュンヘン 2013. 2.22

Takaya H, Uemura M, Fujimoto M, Mitoro A, Sawai M, Yoshida M, Yamao J, Morioka C, Kawaratani H, Hayakawa M,
Matsumoto M, Fujimura Y, Fukui H
Evidence of platelet hyperaggregability related to decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute biliary tract infection
Jahrestagung der Gesellschaft fur Hamostase-und Thromboseforschung
ミュンヘン 2013. 2.22

Yoshiji H, Noguchi R, Kaji K, Aihara Y, Namisaki T, Moriya K, Douhara A, Kitade M, Fukui H
Response-guided anti-angiogenic therapy for hepatocellular carcinoma recurrence with clinically available safety agent
AACR Annual Meeting 2013 Washington, DC 2013. 4.10

Aihara Y, Yoshiji H, Noguchi R, Kaji K, Namisaki T, Moriya K, Kitade M, Fukui H
Direct renin inhibitor attenuates rat hepatocarcinogenesisi via anti-angiogenic activity
AACR Annual Meeting 2013 Washington, DC 2013. 4.10

Fujimoto M, Hayakawa M, Matsuyama T, Kato S, Isonishi A, Takaya H, Ishikawa M, Morioka C, Koyama N, Matsumoto M, Fukui H, Fujimura Y, Uemura M
Decreased plasma ADAMTS13 activity during moderate to much consumption of eethanol in healthy volunteers: Differences between normal and heterozygous mutant aldehyde dehydogenase-2 Alleles
The International society on thrombosis and haemostasis Amsterdam 2013. 7. 1

Takaya H, Uemura M, Fujimoto M, Ishii S, Morioka C, Kawaratani H, Hayakawa M, Matsumoto M, Fujimura Y, Fukui H
Decreased ADAMTS13 activity and its clinical significance in patients with idiopathic portal hypertension
The International society on thrombosis and haemostasis Amsterdam 2013. 7. 1

Yoshiji H, Noguchi,R, Namisaki T. Moriya K, Kitade M, Aihara Y, Douhara A, Kawaratani H, Nishimura N, Fukui H
Combined treatment of sorafenib and angiotensin-Ⅱreceptor blocker attenuates preneoplastic lesion development of non-alcoholic steatohepatitis in rats
International Society for Hepatic Sinusoidal Research 大阪 2013. 9.24

Ryuichi Noguchi, Hitoshi Yoshiji, Tadashi Namisaki, Kei Moriya, Mitsuteru Kitade, Yosuke Aihara, Akitoshi Douhara, Hideto Kawaratani, Norihisa Nishimura, and Hiroshi Fukui
Combination of angiotensin-converting enzyme inhibitor and selective aldosterone blocker, suppresses the liver fibrosis and carcinogenesis of nonalcoholic steatohepatitis in the rat.
International Society for Hepatic Sinusoidal Research 大阪 2013. 9.24

Akitoshi Douhara, Kei Moriya, Hitoshi Yoshiji, Ryuichi Noguchi, Tadashi Namisaki, Mitsuteru Kitade, Yosuke Aihara, Hideto kawaratani, Norihisa Nishimura, Hiroshi Fukui
nhibition of endotoxin cascade with antibiotics attenuates the liver fibrosis development in rat model of nonalcoholic steatohepatitis
International Society for Hepatic Sinusoidal Research 大阪 2013. 9.24

Kitade M, Yoshiji H, Snorri T, Fukui H
Distinct role of EGFR and Met on adult hepatic progenitor cell differentiation in mice
Annual Meeting of the Japanese Society for the Research of Hepatic Cells
大阪 2013. 9.26

Namisaki T, Yoshiji H, Noguchi R, Moriya K, Kitade M, Aihara Y, Douhara A, Kawaratani H, Nishimura N, Fukui H
Beneficial effects of combined treatment with ursodoxycholic acid (UDCA) and Angiotensin-Ⅱtype1 receptor blocker(ARB) on liver fibrosis development in the rat model of nonalcoholic steatohepatitis
Annual Meeting of the Japanese Society for the Research of Hepatic Cells
大阪 2013. 9.26

 

2012

Fujimoto M
Endotoxin activity as a novel marker reflecting decompensation in patients with liver cirrhosis
IEIIS2012 東京 2012.10.24

Takaya H
Endotoxin innate immunity and platelet aggregation in acute liver failure: new therapeutic approach by TLR4 regulation
IEIIS2012 東京 2012.10.24

Kawaratani H
Therapeutic effect of cytokine modulator Y-40138 in the rat alcoholic liver disease model
IEIIS2012 東京 2012.10.24

Takaya H
Potential role of endotoxemia on the decreased activity of plasma ADAMTS13 in patients with chronic and  acute hepatic failure
IEIIS2012 東京 2012.10.24

Kawaratani H
Expression of TLR4 and TNF-a in the rat dextran sulfate sodium(DSS) induced colitis model
IEIIS2012 東京 2012.10.24

Douhara A, Moriya K, Yoshiji H, Noguchi R, Namisaki T, Kaji K, Aihara Y, Yamao J, Mitoro A, Fukui H
Effect of sorafenib on HCV-related hepatocellular carcinoma (HCC)
JSH Single Topic Conference 東京 2012.11.21

Aihara Y, Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kaji K, Douhara A, Fukui H
Crosstalk between glucose intolerance and liver fibrosis development in patients with chronic hepatitis C
JSH Single Topic Conference 東京 2012.11.21

Moriya K, Yoshiji H, Noguchi R, Namisaki T, Kaji K, Douhara A, Aihara Y, Yamao J, Mitoro A, Fukui H
Efficacy of combination therapy with peg-interferon alpha and ribavirin in elderly chronic hepatitic C
JSH Single Topic Conference 東京 2012.11.21

Yoshiji H
Chemoprevention of HCV-associated HCC by BCAA and ACE-inhibitor
JSH Single Topic Conference 東京 2012.11.21

 

2011

Yoshiji H, Ikenaka Y, Noguchi R, Kaji K, Aihara Y, Fukui H.
Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic chemopreventive therapy with clinically available safe agents
ILCA Hong Kong 2011. 9. 3

Noguchi R, Yoshiji H, Ikenaka Y, Aihara Y, Fukui H.
Clinically available selective aldosterone blocker attenuates hepatocarcinogenesis via angiogenesis inhibition in rats
ILCA Hong Kong 2011. 9. 3

Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Fukui H.
Inhibtory effect of selective aldosterone blocker on hepatocellular carcinoma development via angiogenesis suppression
ILCA Hong Kong 2011. 9. 3

Aihara Y, Yoshiji H, Ikenaka Y, Noguchi R, Kaji K, Fukui H.
Combination of branched-amino acids and angiotensin-converting enzyme inhibitor attenuates the insulin resistance -based hepatocarcinogenesis via angiogenesis suppression
ILCA Hong Kong 2011. 9. 3

Fukui H, Uemura M, Fujimoto M.
Effect of interferon therapy on the development of hepatocellular carcinoma and the survival in patients with chronic hepatitis type C
APPLE (ASIA-PACIFIC PRIMARY LIVER CANCER EXPERT MEETING) OSAKA 2011. 7. 3

Yoshiji H, Ikenaka Y, Noguchi R, Kaji K, Aihara Y, Fukui H.
Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma under the condition of insulin resistance
APPLE (ASIA-PACIFIC PRIMARY LIVER CANCER EXPERT MEETING) OSAKA 2011. 7. 3

Noguchi R, Yoshiji H, Ikenaka Y, Kaji K, Shirai Y, Fukui H.
Clinically available selective aldosterone blocker attenuates hepatocarcinogenesis via angiogenesis inhibition in rats
APPLE (ASIA-PACIFIC PRIMARY LIVER CANCER EXPERT MEETING) OSAKA 2011. 7. 3

Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Fukui H.
Inhibitory effect of selective aldosterone blocker on hepatocellular carcinoma development via angiogenesis suppression
APPLE (ASIA-PACIFIC PRIMARY LIVER CANCER EXPERT MEETING) OSAKA 2011. 7. 3

Aihara Y, Yoshiji H, Ikenaka Y, Noguchi R, Kaji K, Fukui H.
Combination of branched-amino acids and angiotensin-converting enzyme inhibitor attenuates the insulin resintance-based hepatocarcinogenesis via angiogenesis suppression
APPLE (ASIA-PACIFIC PRIMARY LIVER CANCER EXPERT MEETING) OSAKA 2011. 7. 3

Yoshjii H.
Renin-angiotensin system in liver fibrogenesis: possible therapeutic implications
Choshu International Liver Symposium 2011 YAMAGUCHI 2011. 1.29

2010

Hitoshi Yoshiji, Yasuhide Ikenaka, Ryuichi Noguchi, Kosuke Kaji, Yusaku Shirai, Hiroshi Fukui.
An alternative VEGF-targeted therapy and possible prediction against hepatocellular carcinoma (HCC) using combination of clinically available agents
AACR 101st Annual Meeting 2010 in Washington, DC

Ryuichi Noguchi, Hitoshi Yoshiji, Yasuhide Ikenaka, Kosuke Kaji, Yusaku Shirai, Hiroshi Fukui.
Clinically used selective aldosterone blocker attenuates hepatocarcinogenesis via angiogenesis inhibition in rats
AACR 101st Annual Meeting 2010 in Washington, DC

Kosuke Kaji, Hitoshi Yoshiji, Yasuhide Ikenaka, Ryuichi Noguchi, Yusaku Shirai, and Hiroshi Fukui
Selective aldosterone blocker inhibits murine hepatocellular carcinoma development via angiogenesis suppression
AACR 101st Annual Meeting 2010 in Washington, DC

Yusaku Shirai, Hitoshi Yoshiji, Yasuhide Ikenaka, Ryuichi Noguchi, Kosuke Kaji, and Hiroshi Fukui
Combination of branched-amino acids and ACE inhibitor attenuates the insulin resistance-based hepatocarcinogenesis via angiogenesis suppression
AACR 101st Annual Meeting 2010 in Washington, DC

2009

Yoshiji H, Noguchi R, Kitade M, Kaji K, Ikenaka Y, Namisaki T, Aihara Y, Fukui H
VEGF-targeted therapy against insulin-resistance-based rat hepatocarcinogenesis with clinically available agent: branched-chain amino acid(BCAA) granules
APASL 19  Hong Kong 2009.2.14

Noguchi R, Yoshiji H, Ikenaka Y, Kitade M, Kaji K, Namisaki T, Aihara Y, Fukui H
Suppressive effect on the cumulative recurrence of hepatocellular carcinoma with combination treatment of clinically available vitamin K2 and angiotensin-converting enzyme inhibitor
APASL 19  Hong Kong 2009.2.14

Namisaki T, Yoshiji H, Noguchi R, Kitade M, Kaji K, Aihara Y, Fukui H
A new therapic strategy for acute hepatic failure with vascular endothelial growth factor(VEGF), a potent angiogenic factor, in rats.
APASL 19  Hong Kong 2009.2.14

Kitade M, Yoshiji H, Noguchi R, Kaji K, Namisaki T, Aihara Y, Fukui H
Neovascularization is required for carcinogenesis of non-alcoholic steatohepatitis: experimental and clinical study
APASL 19  Hong Kong 2009.2.14

Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, Aihara Y, Namisaki T, Fukui H
Insulin resistance plays a pivotal role in the liver fibrosis development and hepatocarcinogenesis in rats
APASL 19  Hong Kong 2009.2.14

Aihra Y, Yoshiji H, Noguchi R, Namisaki T, Kitade M, Kaji K, Fukui H
A clinical case of hepatocellular carcinoma which developped 13 years after sustained virological response to ineterferon therapy against chronic hepatitis C
APASL 19  Hong Kong 2009.2.14

2008

Tsujimoto T, Kawaratani H, Kitazawa T, Fukui H
Decreased contrast effect of contrast enhanced ultrasound in a rat nonalcoholic steatohepatitis model
APASL 18 Soeul, Korea 2008.3.24

Kawaratani H, Tsujimoto T, Kitazawa T, Fukui H
Innate immune response of noalcoholic steatohepatitis(NASH) in rats
APASL 18  Soeul, Korea 2008.3.24

Tsujimoto T, Kwaratani H, Kitazawa T, Uemura M, Fukui H
Y-40138, a multiple cytokine production modulator, inhibits the progression of nonalcoholic steatohepatitis (NASH) in rats - prospects of a new immunotherapy
IEIS 10 Edingburgh, Scotland, UK 2008.7.30-8.2

Kitazawa T, Fukui H, Tsujimoto T, Kawaratani H
New therapeutic approach to acute liver failure through Toll-like receptor 4 regulation
IEIS 10 Edingburgh, Scotland, UK 2008.7.30-8.2

Kawaratani H, Tsujimoto T, Kitazawa T, Uemura M, Fukui H
Role of the innate immunity surrounding TLR4 in the rat nonalcoholic steatohepatitis (NASH)
IEIS 10 Edingburgh, Scotland, UK 2008.7.30-8.2

Fukui H, Kitazawa T, Tsujimoto T, Kawaratani H, Hoppou K, Kitano H, Y. Nakatani Y, Fujimoto M
Endotoxin and acute liver failure: New therapeutic approach by regulation of macrophage innate immunity
UEGW 2008 Vienna, Austria 2008.10.18-10.22